Amneal Pharmaceuticals (NYSE:AMRX) had its target price decreased by equities research analysts at SunTrust Banks from $16.00 to $9.00 in a report issued on Thursday, The Fly reports. The firm presently has a “buy” rating on the stock. SunTrust Banks’ price target indicates a potential upside of 143.24% from the stock’s current price. SunTrust Banks also issued estimates for Amneal Pharmaceuticals’ Q2 2019 earnings at $0.14 EPS.

Several other equities analysts have also weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price objective (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. BMO Capital Markets raised their target price on Sun Life Financial from C$58.00 to C$60.00 in a report on Friday, May 10th. ValuEngine downgraded Whiting USA Trust II from a “hold” rating to a “sell” rating in a report on Tuesday, May 7th. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Raymond James raised their target price on S&P Global from $226.00 to $246.00 and gave the company an “outperform” rating in a report on Wednesday. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $14.58.

NYSE AMRX opened at $3.70 on Thursday. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of 4.35, a P/E/G ratio of 0.25 and a beta of 1.50. Amneal Pharmaceuticals has a 1-year low of $3.69 and a 1-year high of $24.48. The company has a quick ratio of 1.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.44. The company has a 50-day moving average price of $7.12.

Amneal Pharmaceuticals (NYSE:AMRX) last released its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.07). The firm had revenue of $446.00 million during the quarter, compared to analyst estimates of $438.18 million. Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. On average, equities analysts expect that Amneal Pharmaceuticals will post 0.91 earnings per share for the current fiscal year.

In other Amneal Pharmaceuticals news, SVP Joseph Todisco acquired 15,000 shares of the company’s stock in a transaction on Monday, May 13th. The shares were bought at an average cost of $9.88 per share, for a total transaction of $148,200.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Andrew S. Boyer acquired 19,000 shares of the company’s stock in a transaction on Monday, May 13th. The shares were acquired at an average price of $9.46 per share, for a total transaction of $179,740.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 41,000 shares of company stock worth $387,300 over the last 90 days. 26.34% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. Bessemer Group Inc. bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $34,000. Quantamental Technologies LLC increased its holdings in shares of Amneal Pharmaceuticals by 34.0% in the 1st quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock valued at $95,000 after acquiring an additional 1,700 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Amneal Pharmaceuticals by 785.6% in the 1st quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after acquiring an additional 10,347 shares during the last quarter. First Mercantile Trust Co. increased its holdings in shares of Amneal Pharmaceuticals by 40.9% in the 1st quarter. First Mercantile Trust Co. now owns 11,932 shares of the company’s stock valued at $169,000 after acquiring an additional 3,461 shares during the last quarter. Finally, Amalgamated Bank bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $174,000. Institutional investors own 36.05% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Story: Investing in Growth Stocks

The Fly

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.